Michael J Keating Selected Research

B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

1/2022	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
1/2022	STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
1/2021	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
1/2021	The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
1/2020	Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.
1/2020	AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
1/2020	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
12/2019	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.
11/2019	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
4/2019	PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael J Keating Research Topics

Disease

168	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2002
61	Neoplasms (Cancer) 01/2021 - 02/2002
30	Leukemia 01/2021 - 05/2002
13	Lymphoma (Lymphomas) 06/2017 - 02/2002
12	Residual Neoplasm 11/2019 - 01/2003
12	Infections 06/2017 - 05/2002
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2019 - 11/2002
11	Disease Progression 05/2017 - 12/2003
10	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 05/2006
7	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 08/2002
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2011 - 06/2004
6	Lymphocytosis 07/2015 - 09/2006
6	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 09/2011 - 04/2002
6	B-Cell Lymphoma (Lymphoma, B Cell) 05/2011 - 02/2002
5	Diarrhea 01/2020 - 06/2013
5	Mitochondrial Diseases (Mitochondrial Disease) 12/2017 - 04/2009
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2015 - 11/2002
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2012 - 05/2002
5	Prolymphocytic Leukemia 01/2003 - 02/2002
4	Cytopenia 01/2016 - 05/2006
4	Trisomy (Trisomies) 07/2015 - 08/2002
4	Anemia 06/2013 - 10/2002
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2013 - 04/2002
4	Philadelphia Chromosome 08/2010 - 05/2002
3	Vomiting 01/2020 - 09/2003
3	Neutropenia 04/2014 - 05/2006
3	Hypoxia (Hypoxemia) 09/2011 - 01/2005
3	Hairy Cell Leukemia 06/2006 - 11/2002
3	Multiple Myeloma 01/2006 - 11/2002
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2003 - 02/2002
2	Nausea 01/2020 - 09/2003
2	Epstein-Barr Virus Infections 06/2017 - 05/2006
2	Virus Diseases (Viral Diseases) 06/2017 - 09/2006
2	Atrial Fibrillation 11/2016 - 12/2014
2	Primary Myelofibrosis (Myelosclerosis) 05/2016 - 05/2006
2	Colitis 01/2016 - 01/2015

Drug/Important Bio-Agent (IBA)

41	Rituximab (Mabthera)FDA Link 11/2019 - 02/2002
41	fludarabineIBA 11/2019 - 04/2002
25	ibrutinibIBA 01/2020 - 02/2012
23	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2019 - 02/2002
17	Monoclonal AntibodiesIBA 10/2015 - 02/2002
16	Proteins (Proteins, Gene)FDA Link 04/2019 - 01/2003
15	Alemtuzumab (Campath)FDA Link 08/2011 - 05/2002
13	Biological ProductsIBA 04/2019 - 08/2002
12	Lenalidomide (CC 5013)FDA Link 01/2019 - 04/2008
12	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2018 - 06/2003
11	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020 - 02/2012
10	MicroRNAs (MicroRNA)IBA 01/2019 - 04/2009
9	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2018 - 04/2002
8	Pharmaceutical PreparationsIBA 10/2016 - 02/2002
8	Antineoplastic Agents (Antineoplastics)IBA 09/2011 - 05/2003
7	Phosphotransferases (Kinase)IBA 01/2021 - 02/2012
7	Messenger RNA (mRNA)IBA 12/2011 - 06/2005
6	idelalisibIBA 03/2017 - 09/2011
6	RNA (Ribonucleic Acid)IBA 12/2011 - 06/2005
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2003
5	Alkylating AgentsIBA 03/2017 - 02/2002
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 09/2003
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2015 - 04/2002
5	Adenosine Triphosphate (ATP)IBA 10/2012 - 01/2005
5	Immunoglobulins (Immunoglobulin)IBA 04/2009 - 12/2003
5	AntigensIBA 05/2008 - 02/2002
5	Mitochondrial DNA (mtDNA)IBA 12/2006 - 09/2003
5	NucleosidesIBA 06/2006 - 12/2003
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2014 - 12/2006
4	CytokinesIBA 12/2013 - 08/2002
4	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2013 - 05/2009
4	DNA (Deoxyribonucleic Acid)IBA 04/2011 - 12/2003
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2009 - 09/2004
4	triphosphoric acid (triphosphate)IBA 03/2008 - 12/2003
3	venetoclaxIBA 01/2022 - 08/2015
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 05/2009
3	EnzymesIBA 01/2017 - 11/2002
3	ChemokinesIBA 12/2013 - 03/2009
3	Hemoglobins (Hemoglobin)IBA 01/2009 - 10/2002
3	OligonucleotidesIBA 01/2009 - 08/2005
3	Clofarabine (Clolar)FDA Link 07/2006 - 12/2003
3	Cladribine FDA LinkGeneric 07/2006 - 01/2003
3	Imatinib Mesylate (Gleevec)FDA Link 06/2004 - 05/2002
2	Apoptosis Regulatory ProteinsIBA 01/2022 - 01/2021
2	ofatumumab FDA Link 01/2020 - 01/2016
2	Nonesterified Fatty Acids (NEFA)IBA 11/2018 - 01/2016
2	Tyrosine (L-Tyrosine)FDA Link 11/2017 - 04/2010
2	Antigen Receptors (Antigen Receptor)IBA 10/2017 - 06/2011
2	Bendamustine Hydrochloride FDA Link 03/2017 - 06/2014
2	Glutathione (Reduced Glutathione)IBA 01/2017 - 11/2016
2	Serine (L-Serine)FDA Link 01/2017 - 04/2010
2	AntioxidantsIBA 01/2017 - 03/2004
2	carfilzomibIBA 09/2016 - 01/2015
2	Ligases (Synthetase)IBA 01/2016 - 04/2009
2	Immunoglobulin M (IgM)IBA 01/2016 - 04/2005
2	LipidsIBA 01/2016 - 05/2015

Therapy/Procedure

60	Therapeutics 01/2020 - 05/2002
17	Drug Therapy (Chemotherapy) 06/2017 - 11/2002
6	Stem Cell Transplantation 05/2017 - 01/2004
5	Aftercare (After-Treatment) 01/2016 - 05/2002
4	Salvage Therapy 01/2018 - 04/2008
4	Immunotherapy 07/2011 - 01/2003
3	Transplantation 01/2019 - 05/2007
2	Immunomodulation 12/2019 - 01/2004